Our
Clients
: Aug, 2020
: 100
:
Global Pulmonary Arterial Hypertension Market Analysis by Drug Type, Route Of Administration, Distributional Channel, Region and segments forecast till 2033
Market Overview
The global pulmonary arterial hypertension market was worth USD 7,000 million in 2022 and is poised to expand at a CAGR of 5.2% over the forecast period of 2023-2033, thereby amassing USD 11,000 million by end of the assessment period.
Report Scope
Report Attributes | Description |
Market Forecast in 2022 | USD 7,000 Million |
Market Forecast in 2033 | USD 11,000 Million |
CAGR % 2023-2033 | 5.2% |
Base Year | 2022 |
Historic Data | 2020-2021 |
Forecast Period | 2023-2033 |
Report USP | Product Product, end-user industry, company share, company heatmap, company Capacity Technology Product capacity, growth factors and more |
Segments Covered | drug type, route of administration, distributional channel |
Regional Scope | North America, Europe, APAC, South America and Middle East and Africa |
Country Scope | U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria |
Key Companies | Arena Pharmaceuticals (Pfizer Inc.), Bayer AG, GlaxoSmithKline plc, Johnson & Johnson (Actelion Pharmaceuticals, Ltd.), Merck & Co., Inc., United Therapeutics Corporation, Gilead Sciences, Inc., Sandoz AG (Novartis), Lupin, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddys Laboratories Ltd., Par Pharmaceutical, Zydus Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sigmapharm Laboratories, LLC., and Others. |
Global Pulmonary Arterial Hypertension Market: Description
Pulmonary arterial hypertension (PAH) refers to a progressive medical disorder characterized by abnormally high blood pressure in the pulmonary artery. It predominantly occurs when the small arteries present across the lungs narrow down, thereby increasing resistance to blood flow through the lungs. Hence, to overcome this resistance, blood pressure increases in the right ventricle of the heart along with the pulmonary artery. The major symptoms associated with PAH are dyspnea, dizziness, irregular heartbeats, swelling in legs, and chest pain.
The primary factors aiding the industry growth are surging prevalence of PAH worldwide, rise in geriatric population, drug developments along with technological advancements in the field. Moreover, unhealthy lifestyle habits of the masses, rising rate of product approvals by regulatory bodies, and increase in research & development investments in the healthcare sector are positively swaying the market dynamics. On the contrary, side effects pertaining to PAH drugs and patent expiration of drug molecule are likely to hinder the industry progression in the forthcoming years.
With rapid urbanization, there has been a drastic change in the lifestyle habits of the masses. Increasing consumption of ready to eat food and hectic work schedule is severely impacting the health of individuals across the globe. Moreover, excessive smoking and alcohol consumption along with unhealthy diet are the major catalysts aiding the overall market expansion.
Prominent players and medical research entities are increasing their focus towards the development of efficient drugs to treat PAH. They are steadily emphasizing upon the identification of new molecular pathways to develop better treatment options. These factors in turn are accelerating the progression of pulmonary arterial hypertension industry.
Global Pulmonary Arterial Hypertension Market- Segmental Analysis:
Drug Type Insights
The prostacyclin and prostacyclin analogs segment is anticipated to garner significant returns over the forecast duration. This is credited to the escalating demand of this drugs due to their efficacy and easy approval process.
Route of Administration Insights
The oral segment is presently dominating the market in terms of revenue share ascribing to the rising availability of oral formulations and surging patient preference for oral medicines.
Distributional Channel Insights
The online pharmacies segment is slated to register notable gains over 2023-2033 due to increase in internet penetration and widespread adoption of smart devices.
Regional Insights
Considering the geographical frame of reference, the business sphere is divided into North America, Middle East & Africa, Latin America, Europe, and Asia Pacific. Among these, North America is projected to showcase lucrative expansion trends attributing to growing cognizance of PAH, favorable medical reimbursement policies, and surging prevalence of infectious and chronic diseases.
Also, Asia Pacific is anticipated to amplify with a significant CAGR owing to the presence of prominent pharmaceutical companies, surging consumption of generics, and rapidly evolving healthcare infrastructure in nations such as China, India, and Japan.
Competitive Analysis
The noteworthy players influencing the trends of this market sphere are Arena Pharmaceuticals (Pfizer Inc.), Bayer AG, GlaxoSmithKline plc, Johnson & Johnson (Actelion Pharmaceuticals, Ltd.), Merck & Co., Inc., United Therapeutics Corporation, Gilead Sciences, Inc., Sandoz AG (Novartis), Lupin, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddys Laboratories Ltd., Par Pharmaceutical, Zydus Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sigmapharm Laboratories, LLC., and Others.
Global Pulmonary Arterial Hypertension Market- Segmental Analysis
By drug type
Endothelin Receptor Antagonists (ERAs)
PDE-5 Inhibitors
Prostacyclin and Prostacyclin Analogs
SGC Stimulators
Others
By route of administration
Oral
Intravenous/subcutaneous
Inhalational
By distributional channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Why to buy this Report?
Market research: The report provides valuable insights into market trends, growth opportunities, and competitive landscapes. By reading a technology report, businesses and investors can gain a better understanding of the market they are operating in or considering entering, and make more informed decisions based on data and analysis.
Competitive analysis: The report reports provide detailed information on competitors' strengths, weaknesses, and strategies, which can help businesses identify potential threats and opportunities in the market.
Innovation: The report provides insights into emerging technologies and trends, which can help businesses stay up-to-date with the latest developments and make informed decisions about where to invest their resources.
Due diligence: The report can be used by investors and acquirers as part of their due diligence process when considering investing in or acquiring a technology company. These reports can provide valuable information on the company's financials, technology, market position, and other key factors.
1. Global Pulmonary Arterial Hypertension Market Introduction and Market Overview
1.1. Objective of the Market Research Study
1.2. Pulmonary Arterial Hypertension Market Definition & Description
1.3. Research Data Parameters & Reporting Timelines
1.3.1. Historical Data Reporting Years 2020 to 2021
1.3.2. Projected Data Reporting Years 2022 to 2033
1.3.3. Reporting Data Parameters Value (US$ Million)
1.4. Global Pulmonary Arterial Hypertension Market Scope and Market Estimation
1.4.1. Global Pulmonary Arterial Hypertension Overall Market Size (US$ Million), Market CAGR (%), Market Estimates & Forecast (2020 to 2033)
1.4.2. Global Pulmonary Arterial Hypertension Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2020 to 2033
1.5. Pulmonary Arterial Hypertension Market Segmentation
1.5.1. Drug Type of Global Pulmonary Arterial Hypertension Market
1.5.2. Route of Administration of Global Pulmonary Arterial Hypertension Market
1.5.3. Distribution Channel of Global Pulmonary Arterial Hypertension Market
1.5.4. Key Regions of Global Pulmonary Arterial Hypertension Market
2. Global Pulmonary Arterial Hypertension Market - Executive Summary
2.1. Global Pulmonary Arterial Hypertension Market Summary & Snapshot
2.2. Global Pulmonary Arterial Hypertension Market, By Drug Type (US$ Million)
2.3. Global Pulmonary Arterial Hypertension Market, By Route of Administration (US$ Million)
2.4. Global Pulmonary Arterial Hypertension Market, By Distribution Channel (US$ Million)
2.5. Global Pulmonary Arterial Hypertension Market, By Geography (US$ Million)
2.6. Global Pulmonary Arterial Hypertension Market Outlook & Future Opportunities
3. Pulmonary Arterial Hypertension Market Trends, Outlook, and Factors Analysis
3.1. Global Pulmonary Arterial Hypertension Market Industry Development Trends under COVID-19 Outbreak
3.1.1. Global COVID-19 Status Overview
3.1.2. Influence of COVID-19 Outbreak on Global Pulmonary Arterial Hypertension Market Industry Development
3.1.3. Pre & Post COVID-19 Trends and Scenarios
3.2. Pulmonary Arterial Hypertension Market Dynamics (Growth Impacting Factors & Rationales)
3.2.1. Drivers
3.2.1.1. Rising cases of heart problems leading to pulmonary arterial hypertension (PHA) is expected to drive the market growth
3.2.1.2. Growing government initiatives are anticipated to trigger the market growth
3.2.2. Restraints
3.2.2.1. Patent expiration of drug molecule and side effects associated with the drugs is anticipated to hamper the market growth
3.2.3. Opportunities
3.2.3.1. High proportion of children suffering from untreated PAH offers immense market expansion opportunities
3.2.4. Impact Analysis of Drivers and Restraints
3.3. Ecosystem/ Value Chain Analysis
3.4. Porters Five Forces Analysis
3.5. SWOT Analysis
3.6. PEST Analysis
3.7. Average Selling Prices and Pricing Trends Analysis of Pulmonary Arterial Hypertension Market
3.8. Technological Roadmap
3.9. Key Investment Pockets of Pulmonary Arterial Hypertension Market
3.9.1. By Drug Type
3.9.2. By Route of Administration
3.9.3. By Distribution Channel
3.9.4. By Regions
4. Global Pulmonary Arterial Hypertension Market: Estimates & Historic Trend Analysis (2020 to 2021)
4.1. Global Pulmonary Arterial Hypertension Market, 2020 2021 (US$ Million)
4.2. Global Pulmonary Arterial Hypertension Market, By Drug Type, 2020 to 2021 (US$ Million)
4.3. Global Pulmonary Arterial Hypertension Market, By Route of Administration, 2020 to 2021 (US$ Million)
4.4. Global Pulmonary Arterial Hypertension Market, By Distribution Channel, 2020 to 2021 (US$ Million)
4.5. Global Pulmonary Arterial Hypertension Market, By Region, 2020 to 2021 (US$ Million)
5. Global Pulmonary Arterial Hypertension Market Estimates & Forecast Trend Analysis, by Drug Type
5.1. Global Pulmonary Arterial Hypertension Market Share (%) Estimates and Forecasts, by Drug Type, 2022 & 2033
5.2. Global Pulmonary Arterial Hypertension Market Revenue (US$ Million) Estimates and Forecasts, by Drug Type, 2022 to 2033
5.2.1. Endothelin Receptor Antagonists (ERAs)
5.2.2. PDE-5 Inhibitors
5.2.3. Prostacyclin and Prostacyclin Analogs
5.2.4. SGC Stimulators
5.2.5. Others
6. Global Pulmonary Arterial Hypertension Market Estimates & Forecast Trend Analysis, by Route of Administration
6.1. Global Pulmonary Arterial Hypertension Market Share (%) Estimates and Forecasts, by Route of Administration, 2022 & 2033
6.2. Global Pulmonary Arterial Hypertension Market Revenue (US$ Million) Estimates and Forecasts, by Route of Administration, 2022 to 2033
6.2.1. Oral
6.2.2. Intravenous/ subcutaneous
6.2.3. Inhalational
7. Global Pulmonary Arterial Hypertension Market Estimates & Forecast Trend Analysis, by Distribution Channel
7.1. Global Pulmonary Arterial Hypertension Market Share (%) Estimates and Forecasts, by Distribution Channel, 2022 & 2033
7.2. Global Pulmonary Arterial Hypertension Market Revenue (US$ Million) Estimates and Forecasts, by Distribution Channel, 2022 to 2033
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
8. Global Pulmonary Arterial Hypertension Market Analysis and Forecast, by Region
8.1. Global Pulmonary Arterial Hypertension Market Share (%) Estimates and Forecasts, by Region, 2022 & 2033
8.2. Global Pulmonary Arterial Hypertension Market Revenue (US$ Million) Estimates and Forecasts, by Region, 2022 to 2033
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Middle East and Africa
8.2.5. Latin America
9. North America Pulmonary Arterial Hypertension Market: Estimates & Forecast Trend Analysis
9.1. North America Pulmonary Arterial Hypertension Market Assessments & Key Findings
9.2. North America Pulmonary Arterial Hypertension Market Share (%) Estimates and Forecasts, 2022 & 2033
9.3. North America Pulmonary Arterial Hypertension Market Size Estimates and Forecast (US$ Million) (2022 to 2033)
9.3.1. By Drug Type
9.3.2. By Route of Administration
9.3.3. By Distribution Channel
9.3.4. By Major Country
9.3.4.1. The U.S.
9.3.4.2. Canada
10. Europe Pulmonary Arterial Hypertension Market: Estimates & Forecast Trend Analysis
10.1. Europe Pulmonary Arterial Hypertension Market Assessments & Key Findings
10.2. Europe Pulmonary Arterial Hypertension Market Share (%) Estimates and Forecasts, 2022 & 2033
10.3. Europe Pulmonary Arterial Hypertension Market Size Estimates and Forecast (US$ Million) (2022 to 2033)
10.3.1. By Drug Type
10.3.2. By Route of Administration
10.3.3. By Distribution Channel
10.3.4. By Major Country
10.3.4.1. Germany
10.3.4.2. The U.K.
10.3.4.3. France
10.3.4.4. Italy
10.3.4.5. Spain
10.3.4.6. Rest of Europe (includes all other European countries)
11. Asia Pacific Pulmonary Arterial Hypertension Market: Estimates & Forecast Trend Analysis
11.1. Asia Pacific Pulmonary Arterial Hypertension Market Assessments & Key Findings
11.2. Asia Pacific Pulmonary Arterial Hypertension Market Share (%) Estimates and Forecasts, 2022 & 2033
11.3. Asia Pacific Pulmonary Arterial Hypertension Market Size Estimates and Forecast (US$ Million) (2022 to 2033)
11.3.1. By Drug Type
11.3.2. By Route of Administration
11.3.3. By Distribution Channel
11.3.4. By Major Country
11.3.4.1. China
11.3.4.2. Japan
11.3.4.3. India
11.3.4.4. ASEAN
11.3.4.5. South Korea
11.3.4.6. Rest of Asia Pacific (includes all other Asia Pacific countries)
12. Middle East & Africa Pulmonary Arterial Hypertension Market: Estimates & Forecast Trend Analysis
12.1. Middle East & Africa Pulmonary Arterial Hypertension Market Assessments & Key Findings
12.2. Middle East & Africa Pulmonary Arterial Hypertension Market Share (%) Estimates and Forecasts, 2022 & 2033
12.3. Middle East & Africa Pulmonary Arterial Hypertension Market Size Estimates and Forecast (US$ Million) (2022 to 2033)
12.3.1. By Drug Type
12.3.2. By Route of Administration
12.3.3. By Distribution Channel
12.3.4. By Major Country
12.3.4.1. GCC
12.3.4.2. South Africa
12.3.4.3. Egypt
12.3.4.4. Rest of Middle East & Africa (includes all other Middle East & Africa countries)
13. Latin America Pulmonary Arterial Hypertension Market: Estimates & Forecast Trend Analysis
13.1. Latin America Market Assessments & Key Findings
13.2. Latin America Pulmonary Arterial Hypertension Market Share (%) Estimates and Forecasts, 2022 & 2033
13.3. Latin America Pulmonary Arterial Hypertension Market Size Estimates and Forecast (US$ Million) (2022 to 2033)
13.3.1. By Drug Type
13.3.2. By Route of Administration
13.3.3. By Distribution Channel
13.3.4. By Major Country
13.3.4.1. Brazil
13.3.4.2. Mexico
13.3.4.3. Rest of Latin America (includes all other Latin America countries)
14. Competitive Landscape
14.1. Pulmonary Arterial Hypertension Market Revenue Share Analysis (%), by Major Players (2021)
14.2. Pulmonary Arterial Hypertension Market Competition Matrix, by Leading Players
14.3. Pulmonary Arterial Hypertension List of Emerging, Prominent and Leading Players
14.4. Major Mergers & Acquisitions, Partnership, Joint Venture, Expansions, Deals, Recent Developments, etc.
15. Company Profiles
15.1. Arena Pharmaceuticals (Pfizer Inc)
15.1.1. Company Overview & Insights
15.1.2. Financial Performance
15.1.3. Product / Service Portfolio
15.1.4. Geographical Footprint & Share
15.1.5. Strategic Initiatives & Key Developments
*Similar details would be provided for all the players mentioned below
15.2. Bayer AG
15.3. GlaxoSmithKline plc
15.4. Johnson & Johnson (Actelion Pharmaceuticals, Ltd.)
15.5. Merck & Co., Inc
15.6. United Therapeutics Corporation
15.7. Gilead Sciences, Inc.
15.8. Sandoz AG (Novartis)
15.9. Lupin
15.10. Teva Pharmaceutical Industries Ltd.
15.11. Eli Lilly and Company
15.12. DAIICHI SANKYO COMPANY, LIMITED
15.13. Dr. Reddys Laboratories Ltd.
15.14. Par Pharmaceutical
15.15. Zydus Pharmaceuticals, Inc.
15.16. Hikma Pharmaceuticals PLC
15.17. Mylan N.V.
15.18. Sigmapharm Laboratories, LLC.
15.19. Others
16. Assumptions and Research Methodology
16.1. Data Mining
16.2. Secondary Research
16.3. Primary Research
16.4. Subject Matter Expert Advice
16.5. Quality Check
16.6. Final Review
16.7. Data Triangulation
16.8. Bottom-Up Approach
16.9. Top Down Approach
16.10. Research Flow
16.11. Key Insights from Industry Experts
16.12. Data Sources
16.13. Assumptions
16.14. Limitations
17. Conclusions and Recommendations
17.1. Key Research Findings and Conclusion
17.2. Key Insights & Recommendations from Analysts